Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Fol… (NCT07595146) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability
United States100 participantsStarted 2026-08-01
Plain-language summary
The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant. MCP-Dyad is a meaning-focused support program. It is designed to help people stay connected to meaning, cope with difficult experiences, and communicate as a pair during recovery.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Eligible patients and their caregivers must be adults (≥18 years)
* Patient must have undergone HSCT for a malignant blood cancer condition
* Caregiver must be the main support person (e.g., signed caregiving contract) for the HSCT patient
* Both the patient and their caregiver must be willing to participate in the study (dyads only)
* Be able to read, write, and speak in English
* Have access to a smartphone, computer, or tablet necessary for study participation and assessments. If a patient/caregiver dyad is interested in participating but does not have such a device, we will provide a Tracfone with smartphone capabilities for each member of the dyad
Exclusion criteria:
* Patients undergoing HSCT for nonmalignant conditions
* Patients and caregivers with severe cognitive or psychiatric impairment that may affect informed consent/participation
* Prisoners, pregnant women, and institutionalized persons
* Patients with severe cognitive or psychiatric impairment that would affect informed consent or participation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Feasibility to accrue HSCT patient/caregiver dyads
Timeframe: Baseline
2
Completion of MCP-Dyad
Timeframe: End of treatment (approximately 14 weeks)
3
MCP-Dyad Feasibility rating from participants
Timeframe: End of treatment (approximately 14 weeks)
4
MCP-Dyad Retention
Timeframe: End of treatment (approximately 14 weeks)
5
MCP-Dyad Intervention Adherence
Timeframe: End of treatment (approximately 14 weeks)
6
MCP-Dyad acceptability as rated on the Acceptability of Intervention Measure (AIM)
Timeframe: End of treatment (approximately 14 weeks)
7
Change in Intervention Appropriateness Measure (IAM) score
Timeframe: Baseline, End of treatment (approximately 14 weeks)